ArticleBioprocess and biosystems engineering2026
Systematic metabolic engineering of Komagataella phaffii for methanol-to-lactate bioconversion.
Article in Bioprocess and biosystems engineering, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Modular synthetic cross-kingdom promoters enable coordinated expression in Escherichia coli and Saccharomyces cerevisiae.Nucleic acids research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Methanol is an attractive C1 feedstock for sustainable biomanufacturing. However, efficient conversion of methanol into value-added products remains challenging due to metabolic compartmentalization, accumulation of toxic intermediates, and carbon loss in methylotrophic yeasts. In this study, we established a methanol-to-lactate bioconversion platform in Komagataella phaffii through a systematic metabolic engineering strategy that integrates methanol assimilation, detoxification, and downstream carbon flux redirection. Initial expression of a heterologous lactate dehydrogenase enabled efficient lactic acid production from glycerol but failed under methanol conditions, revealing a methanol-specific metabolic bottleneck. Reinforcement of methanol oxidation and oxidative stress mitigation improved methanol utilization and initiated lactic acid production, yet substantial carbon loss persisted through formaldehyde dissimilation. Blocking this dissimilatory pathway led to severe growth defects, suggesting its indispensable role in redox homeostasis and formaldehyde tolerance. In contrast, optimization of the downstream pyruvate node by eliminating competing ethanol formation and enhancing lactate export significantly improved both productivity and yield. The final engineered strain achieved a lactic acid titer of 0.53 g/L with a methanol-based yield of 63.8 mg lactic acid/g methanol. These results reveal that efficient methanol-based lactic acid production requires a holistic strategy that couples robust C1 assimilation with targeted redirection of cytosolic carbon flux and effective product secretion. This work provides a foundational framework for developing scalable C1-based biorefineries for organic acid production.
Indexed as
Identifiers
41931141What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.